BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37601839)

  • 1. An ETV6::NTRK3 fusion transcript in a core-binding factor acute myeloid leukemia.
    Coster L; Huguet F; Canali A; Rieu JB; De Mas VM
    EJHaem; 2023 Aug; 4(3):867-868. PubMed ID: 37601839
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.
    Kralik JM; Kranewitter W; Boesmueller H; Marschon R; Tschurtschenthaler G; Rumpold H; Wiesinger K; Erdel M; Petzer AL; Webersinke G
    Diagn Pathol; 2011 Mar; 6():19. PubMed ID: 21401966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25).
    Eguchi M; Eguchi-Ishimae M; Tojo A; Morishita K; Suzuki K; Sato Y; Kudoh S; Tanaka K; Setoyama M; Nagamura F; Asano S; Kamada N
    Blood; 1999 Feb; 93(4):1355-63. PubMed ID: 9949179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
    Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.
    Sheng WQ; Hisaoka M; Okamoto S; Tanaka A; Meis-Kindblom JM; Kindblom LG; Ishida T; Nojima T; Hashimoto H
    Am J Clin Pathol; 2001 Mar; 115(3):348-55. PubMed ID: 11242790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of RBPJ, an upstream regulator of ETV6 gene, abrogates ETV6-NTRK3 fusion gene transformations in glioblastoma.
    Biswas A; Rajesh Y; Das S; Banerjee I; Kapoor N; Mitra P; Mandal M
    Cancer Lett; 2022 Sep; 544():215811. PubMed ID: 35787922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis.
    Watanabe N; Kobayashi H; Hirama T; Kikuta A; Koizumi S; Tsuru T; Kaneko Y
    Cancer Genet Cytogenet; 2002 Jul; 136(1):10-6. PubMed ID: 12165445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
    Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
    Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
    Rubin BP; Chen CJ; Morgan TW; Xiao S; Grier HE; Kozakewich HP; Perez-Atayde AR; Fletcher JA
    Am J Pathol; 1998 Nov; 153(5):1451-8. PubMed ID: 9811336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.
    Su Z; Liu X; Hu W; Yang J; Yin X; Hou F; Wang Y; Zhang J
    Hematology; 2022 Dec; 27(1):1010-1018. PubMed ID: 36069745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
    Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
    Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene.
    Murga Penas EM; Cools J; Algenstaedt P; Hinz K; Seeger D; Schafhausen P; Schilling G; Marynen P; Hossfeld DK; Dierlamm J
    Genes Chromosomes Cancer; 2003 May; 37(1):79-83. PubMed ID: 12661008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
    Alassiri AH; Ali RH; Shen Y; Lum A; Strahlendorf C; Deyell R; Rassekh R; Sorensen PH; Laskin J; Marra M; Yip S; Lee CH; Ng TL
    Am J Surg Pathol; 2016 Aug; 40(8):1051-61. PubMed ID: 27259007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
    Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
    Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of leukemias with ETV6-ABL1 fusion.
    Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
    Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions.
    Koleilat A; McGarrah PW; Olteanu H; Van Dyke DL; Smadbeck JB; Johnson SH; Vasmatzis G; Hoppman NL; Xu X; Ketterling RP; Greipp PT; Baughn LB; Patnaik MS; Peterson JF
    Cancer Genet; 2022 Jan; 260-261():1-5. PubMed ID: 34781094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
    Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
    Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
    Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
    Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
    Van Limbergen H; Beverloo HB; van Drunen E; Janssens A; Hählen K; Poppe B; Van Roy N; Marynen P; De Paepe A; Slater R; Speleman F
    Genes Chromosomes Cancer; 2001 Mar; 30(3):274-82. PubMed ID: 11170285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.